Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting γc-cytokine activity involve raising neutralizing antibodies against each individual γc-cytokine family member/receptor subunit. However, success has been limited and often multiple γc-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. Such approach allows for flexibility in antagonist design. In several embodiments, peptides exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.

Disclosed is a powder composition consisting essentially of Magnolia officinalis bark extract comprising magnolol and honokiol, tocopherol or tocopherol acetate, lecithin, at least one gum, and optionally water, wherein the composition is in powdered form.

This disclosure relates to new compositions and methods for treating skin conditions as a result of sun damage. In one embodiment this disclosure pertains to new compositions for treating or preventing sunburns, skin damage, and/or harm from radiation, such as UV radiation.

The present disclosure relates to, inter alia, a formulation in a package. The formulation comprises one or more active agents and is co-mingled with a whipping agent prior to being filled under pressure into the package. The whipping agent is added in sufficient amounts to be dispersed in the formulation. The pressurized package is under sufficient pressure suitable to maintain the whipping agent dispersed in the formulation; and the pressurized package is under sufficient pressure to expel the formulation as a whipped formulation upon application of external force on the formulation in the package.

A composition is described comprising probiotics (live and viable or inactivated bacterial strains) and hyaluronic acid or a salt thereof and related use in prevention, treatment (therapeutic or cosmetic curative) or attenuation of at least one sign or symptom associated with, or caused by, skin aging. Use of the composition is also described in prevention or treatment (therapeutic or cosmetic curative) or attenuation of at least one sign or symptom associated with or caused by a reduction in the immune defences of the skin or by an inflammation/infection of the skin, such as an inflammation induced or caused by UV rays.

Suggested is an active mixture, comprising or consisting of: (a) at least one biopolymer; (b) at least one glycosaminoglycan; (c) at least one disaccharide; and optionally (d) at least one active selected from the group consisting of phenols and/or polyphenols.

A composition and method for increasing and/or synchronizing per1 gene expression in skin cells having decreased, irregular, or asynchronous per1 gene expression comprising treating the skin cells with the composition, which contains an effective amount of cichoric acid.

A Borojo skin care product and a preparation method thereof are disclosed. The skin care product comprises a matrix and Borojo powder, and the preparation method thereof comprises the steps: mixing and homogeneously stirring the Borojo powder in the matrix to obtain the Borojo skin care product.

Short tri- and tetrapeptides according to the following Formula I Ar(CH2).sub.mX.sup.1—X.sup.2—CO—X.sup.3—X.sup.4—X.sup.5-(Trp).sub.n-NX.sup.6R are potent, selective agonists of melanocortin 1 receptor (MC1R). Provided herein are pharmaceutical compositions including Formula I peptide agonists of MC1R and methods of treating skin diseases and disorders that include administering to an individual in need thereof a therapeutic amount of a Formula I peptide. The peptides, pharmaceutical compositions, and methods described herein are useful in the treatment of diseases and disorders that benefit from agonism of MCIR, including melanoma, basal cell carcinoma, squamous cell carcinoma, porphyria, polymorphous light eruption, vitiligo, and solar urticaria.

Compositions containing a combination of nicotinamide riboside and pterostilbene for treating skin disorders, and methods of treating skin disorders using these compositions and their equivalents are described. The skin disorders that are treated using these compositions or methods include sun exposure-related skin disorders, inflammatory skin disorders, autoimmune disease-related skin disorders and cancer-related skin disorders. In one embodiment, the compositions containing a combination of nicotinamide riboside and pterostilbene are prepared as oral formulations.